Merck Inc.,, announced results from final analyses of the pivotal Phase III efficacy, immunogenicity, and safety clinical trial for Gardasil...
Merck Inc., known as MSD outside of the United States and Canada, at the EUROGIN 2024 HPV Congress, announced plans to initiate clinical development of a new investigational multi-valent HPV vaccine designed to provide broader protection against multiple HPV types
The FDA has approved a supplemental application for Gardasil 9 (Human Papillomavirus (HPV) 9-valent Vaccine, Recombinant) expanding the approved use...
Merck Inc., known as MSD outside of the United States and Canada, announced positive data from multiple Phase II studies evaluating V 116, the company’s investigational, adult-specific 21-valent pneumococcal conjugate vaccine, at the 13th Meeting of the International Society of Pneumonia and Pneumococcal Diseases (ISPPD) in Cape Town, South Africa
Two studies show the human papillomavirus (HPV) vaccine Cervarix (papillomarvirus vaccine), from GlaxoSmithKline, offers excellent protection against the more serious...
The FDA has approved Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) from Merck Inc., for the prevention of certain diseases...
Merck Inc., has announced that the FDA has accepted for review a new supplemental Biologics License Application (sBLA) for Gardasil...
The FDA has approved an expanded age indication for Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant), to now include use...
Pfizer Inc. announced at the end of 2018, the initiation of a Phase III program for its 20-Valent pneumococcal conjugate...
Pfizer Inc. announced top-line results from a second Phase 111 study (NCT03828617), which described the safety and evaluated the consistency of immune responses elicited across three different lots of its 20-valent pneumococcal polysaccharide conjugate vaccine (20vPnC) candidate in adults 18 through 49 years of age not previously vaccinated against pneumococcal disease.